ANKRD11 and cancer: It has been found that 65K has one site with O‐linked glycan and three phosphorylated serine residues (21, 108, and 381) in human cancer cell lines,[46] and ANKRD11 has many modifications in its 65K‐interacting domain (aa1160‐1470), including the SUMOylated K1446,[47] N‐glycosylated T1425,[48] phosphorylated T1120, S1296, and T1419.[49] Therefore, whether these modifications could affect the 65K‐ANKRD11 interaction and consequentially change their DNA‐binding strength is worth further investigation.